mdl 29311 has been researched along with Alloxan Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dillberger, JE; Heineke, EW; Johnson, MB; Robinson, KM | 1 |
| Barnhart, RL; Heineke, EW; Johnson, MB; Rhinehart, BL; Robinson, KM; Sheetz, MJ | 1 |
2 other study(ies) available for mdl 29311 and Alloxan Diabetes
| Article | Year |
|---|---|
Antioxidant MDL 29,311 prevents diabetes in nonobese diabetic and multiple low-dose STZ-injected mice.
Topics: Aging; Animals; Antioxidants; Atrophy; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Female; Insulin; Islets of Langerhans; Male; Mice; Mice, Inbred NOD; Mice, Inbred Strains; Pancreatic Diseases; Probucol | 1993 |
MDL 29311. Antioxidant with marked lipid- and glucose-lowering activity in diabetic rats and mice.
Topics: Animals; Diabetes Mellitus, Experimental; Fasting; Fatty Acids, Nonesterified; Female; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; Probucol; Rats; Rats, Sprague-Dawley; Time Factors; Triglycerides | 1993 |